This study looked at patient-reported outcomes from 172 subjects with chronic inflammatory demyelinating polyneuropathy (CIDP). Patients were randomly assigned to weekly 0.2 g/kg or 0.4 g/kg bodyweight of 20% subcutaneous immunoglobin (SCIG) or placebo. They then assessed overall quality of life/health status using three different questionnaires: the EuroQoL 5‐Dimension (EQ‐5D) health profile and visual analog scale, the Treatment Satisfaction Questionnaire for Medicine for treatment satisfaction, and the Work Productivity and Activity Impairment Questionnaire for General Health (WPAI ‐GH) for work-related impact. Significantly higher proportions of SCIG-treated patients reported improved/maintained their health status according to the EQ-5D profile. The other two evaluation tools showed more stable scores with SCIG treatment compared to placebo. “IgPro20 (SCIG) maintained or improved quality of life in most subjects with CIDP, consistent with the PATH study findings that both SCIG doses were efficacious in maintaining CIDP,” the authors wrote in their study.
This article was originally published here